Jason Daly Sells 210,000 Shares of Amneal Pharmaceuticals (NASDAQ:AMRX) Stock

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) EVP Jason Daly sold 210,000 shares of the business’s stock in a transaction on Wednesday, August 12th. The shares were sold at an average price of $17.40, for a total transaction of $3,654,000.00. Following the sale, the executive vice president directly owned 35,171 shares of the company’s stock, valued at approximately $611,975.40. The trade was a 85.65% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Amneal Pharmaceuticals Price Performance

Shares of Amneal Pharmaceuticals stock opened at $18.15 on Friday. The stock has a market cap of $5.80 billion, a P/E ratio of 37.04 and a beta of 1.27. The company has a debt-to-equity ratio of 77.65, a quick ratio of 1.44 and a current ratio of 2.20. The stock’s fifty day moving average is $17.24 and its 200 day moving average is $14.59. Amneal Pharmaceuticals, Inc. has a one year low of $9.20 and a one year high of $19.26.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Globeflex Capital L P bought a new position in Amneal Pharmaceuticals in the 2nd quarter worth approximately $2,536,000. Bank of New York Mellon Corp bought a new stake in shares of Amneal Pharmaceuticals during the second quarter valued at approximately $17,573,000. Handelsbanken Fonder AB lifted its holdings in shares of Amneal Pharmaceuticals by 3.0% in the second quarter. Handelsbanken Fonder AB now owns 76,400 shares of the company’s stock worth $1,322,000 after buying an additional 2,200 shares in the last quarter. Bank of America Corp DE lifted its holdings in shares of Amneal Pharmaceuticals by 50.0% in the first quarter. Bank of America Corp DE now owns 676,795 shares of the company’s stock worth $8,413,000 after buying an additional 225,637 shares in the last quarter. Finally, Arkadios Wealth Advisors bought a new position in shares of Amneal Pharmaceuticals during the first quarter worth $4,165,000. 31.82% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

AMRX has been the subject of several analyst reports. Weiss Ratings lowered shares of Amneal Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a report on Wednesday. UBS Group lifted their price target on shares of Amneal Pharmaceuticals from $23.00 to $25.00 and gave the company a “buy” rating in a report on Monday, August 3rd. Zacks Research raised shares of Amneal Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Friday, August 7th. The Goldman Sachs Group restated a “buy” rating and set a $21.00 price objective on shares of Amneal Pharmaceuticals in a research report on Friday, July 31st. Finally, Wall Street Zen upgraded shares of Amneal Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Sunday, July 12th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat, Amneal Pharmaceuticals presently has an average rating of “Buy” and an average price target of $17.67.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.